CC-92480 + Other Drugs for Multiple Myeloma
Trial Summary
CC-92480, also known as Mezigdomide, is unique because it is a cereblon E3 ubiquitin ligase modulator that shows strong activity against multiple myeloma, even in cases resistant to other similar drugs like lenalidomide and pomalidomide. This drug works by targeting specific proteins essential for the growth of myeloma cells, making it a promising option for patients with relapsed or refractory multiple myeloma.
12346Research shows that CC-92480, a cereblon E3 ubiquitin ligase modulating drug, has potent antimyeloma activity. Mezigdomide, a similar drug, has shown strong tumor-killing effects in multiple myeloma models, even in cases resistant to other treatments.
13456The trial information does not specify if you need to stop taking your current medications. However, you cannot have used any systemic anti-myeloma drug therapy within 14 days before starting the study treatment.
The safety of CC-92480 in humans is not directly addressed in the provided research articles. However, it is a cereblon E3 ubiquitin ligase modulator with potent antimyeloma activity, and similar drugs in this class have been used in multiple myeloma treatment. Further clinical trials would be needed to determine its safety in humans.
12456Eligibility Criteria
This trial is for adults with Multiple Myeloma that has come back or didn't respond to treatment. They must have measurable disease, be in good physical condition (ECOG PS of 0 or 1), and not suitable for other effective treatments. Participants can't join if they've had certain prior therapies, recent stem-cell transplants, CNS involvement by MM, recent SARS-CoV-2 infection, major surgery, radiation therapy, anti-myeloma drugs or investigational agents within specific time frames.Inclusion Criteria
Exclusion Criteria